Limits...
Comparative effects of denosumab or bisphosphonate treatment on bone mineral density and calcium metabolism in postmenopausal women

View Article: PubMed Central - PubMed

ABSTRACT

Objectives:: To clarify potential differences between denosumab (DNS) and bisphosphonates (BIS) in terms of bone density and bone metabolism, in a sample of postmenopausal women.

Methods:: A total of 113 postmenopausal women aged 53-66 years were treated with either DNS or BIS for 12 months. Bone densitometry and laboratory tests were compared between baseline and follow-up.

Results:: Femoral neck BMD increased in both treatment-arms (FN-BMD, DNS: 0.69±0.07 g/cm2 to 0.75±0.09 g/cm2 BIS: 0.69±0.06 g/cm2 to 0.71±0.07 g/cm2; p≤0.001 in both cases). Lumbar spine BMD (LS-BMD) increased significantly only in the DNS-group (0.83±0.14 g/cm2 to 0.89±0.14 g/cm2, p=0.0001). Only women under treatment with DNS had a significant increase in serum parathyroid hormone (PTH: 44.87±17.54 pg/mL to 53.27±15.77 pg/mL, p=0.04), independently of baseline vitamin D levels. DNS-administration resulted in higher increase from baseline in FN-BMD compared to BIS (DNS vs BIS: 8.7%±8.5 vs 3.8%±7.3, p=0.004). Finally, baseline 25OH vitamin D levels did not determine the extent of PTH-increase following administration of DNS- or BIS-treatment.

Conclusions:: Both treatments increased BMD, however, the effect of DNS on FN-BMD was superior compared to that of BIS. DNS-treatment increased serum PTH. Baseline 25OH vitamin D levels did not predict the extent of PTH increase at follow-up.

No MeSH data available.


Mean percent changes (SEM) from baseline in femoral neck (FN) and lumbar spine (LS) bone mineral density (BMD) in the two treatment groups. Statistical significance was set at the level of p<0.05.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC5383772&req=5

Figure 1: Mean percent changes (SEM) from baseline in femoral neck (FN) and lumbar spine (LS) bone mineral density (BMD) in the two treatment groups. Statistical significance was set at the level of p<0.05.

Mentions: Percent changes from baseline in the two study groups concerning BMD in the lumbar spine and femoral neck are presented in Figure 1. Denosumab resulted in significantly higher increase in femoral neck BMD compared to bisphosphonates (denosumab 8.7%±8.5, bisphosphonates 3.8%±7.3, p=0.004). The same was apparent for lumbar spine BMD, the difference, however, did not reach statistical significance (denosumab 9.03%±11.3, bisphosphonates 4.5%±11.6, p=0.154). In accordance, T-score increases were higher in the denosumab group compared to the bisphosphonate group, the difference being significant only for femoral neck (% change T-score femoral neck: denosumab 21.2%±20.14, bisphosphonates 7.43%±17.4, p=0.003; % change T-score lumbar spine: denosumab 12.4%±23.0, bisphosphonates 6.3%±29.2, p=0.91). No significant differences between changes in the two groups were observed concerning the biochemical parameters.


Comparative effects of denosumab or bisphosphonate treatment on bone mineral density and calcium metabolism in postmenopausal women
Mean percent changes (SEM) from baseline in femoral neck (FN) and lumbar spine (LS) bone mineral density (BMD) in the two treatment groups. Statistical significance was set at the level of p<0.05.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC5383772&req=5

Figure 1: Mean percent changes (SEM) from baseline in femoral neck (FN) and lumbar spine (LS) bone mineral density (BMD) in the two treatment groups. Statistical significance was set at the level of p<0.05.
Mentions: Percent changes from baseline in the two study groups concerning BMD in the lumbar spine and femoral neck are presented in Figure 1. Denosumab resulted in significantly higher increase in femoral neck BMD compared to bisphosphonates (denosumab 8.7%±8.5, bisphosphonates 3.8%±7.3, p=0.004). The same was apparent for lumbar spine BMD, the difference, however, did not reach statistical significance (denosumab 9.03%±11.3, bisphosphonates 4.5%±11.6, p=0.154). In accordance, T-score increases were higher in the denosumab group compared to the bisphosphonate group, the difference being significant only for femoral neck (% change T-score femoral neck: denosumab 21.2%±20.14, bisphosphonates 7.43%±17.4, p=0.003; % change T-score lumbar spine: denosumab 12.4%±23.0, bisphosphonates 6.3%±29.2, p=0.91). No significant differences between changes in the two groups were observed concerning the biochemical parameters.

View Article: PubMed Central - PubMed

ABSTRACT

Objectives:: To clarify potential differences between denosumab (DNS) and bisphosphonates (BIS) in terms of bone density and bone metabolism, in a sample of postmenopausal women.

Methods:: A total of 113 postmenopausal women aged 53-66 years were treated with either DNS or BIS for 12 months. Bone densitometry and laboratory tests were compared between baseline and follow-up.

Results:: Femoral neck BMD increased in both treatment-arms (FN-BMD, DNS: 0.69&plusmn;0.07 g/cm2 to 0.75&plusmn;0.09 g/cm2 BIS: 0.69&plusmn;0.06 g/cm2 to 0.71&plusmn;0.07 g/cm2; p&le;0.001 in both cases). Lumbar spine BMD (LS-BMD) increased significantly only in the DNS-group (0.83&plusmn;0.14 g/cm2 to 0.89&plusmn;0.14 g/cm2, p=0.0001). Only women under treatment with DNS had a significant increase in serum parathyroid hormone (PTH: 44.87&plusmn;17.54 pg/mL to 53.27&plusmn;15.77 pg/mL, p=0.04), independently of baseline vitamin D levels. DNS-administration resulted in higher increase from baseline in FN-BMD compared to BIS (DNS vs BIS: 8.7%&plusmn;8.5 vs 3.8%&plusmn;7.3, p=0.004). Finally, baseline 25OH vitamin D levels did not determine the extent of PTH-increase following administration of DNS- or BIS-treatment.

Conclusions:: Both treatments increased BMD, however, the effect of DNS on FN-BMD was superior compared to that of BIS. DNS-treatment increased serum PTH. Baseline 25OH vitamin D levels did not predict the extent of PTH increase at follow-up.

No MeSH data available.